Comparison of New Weight Loss Pills: Foundayo and Wegovy
The weight loss medication landscape has expanded with the introduction of two new GLP-1 pills: Wegovy and Foundayo. Wegovy, developed by Novo Nordisk, is an FDA-approved oral semaglutide medication designed for adults with overweight or obesity. It mimics the glucagon-like peptide 1 (GLP-1) to reduce hunger and slow food transit in the gut, helping users feel fuller longer. Foundayo, or orforglipron, created by Lilly, also mimics GLP-1 but is a small molecule rather than a peptide, allowing it to survive digestion without injections or strict fasting protocols. Both medications require starting at a lower dose before increasing to higher doses, and they offer alternatives to injectable weight loss treatments. 
